Ab 2019 wird CTSO einen „Procedure-Code“ in der Schweiz bekommen. Könnte und sollte der erste Schritt vor einem Kostenerstattungsmodell sein, das es in Deutschland seit 2017 gibt.
„Dr. Christian Steiner , Vice President of Sales and Marketing for CytoSorbents explained, ‚We are pleased that our CytoSorb therapy has been so rapidly integrated into the DRG system in Switzerland , one of our main direct sales territories. This was done with the support of all of the university hospitals in Switzerland and a key medical society, demonstrating the importance and acceptance of the therapy in the country. Switzerland’s healthcare system is widely recognized as one of the best in the world, with excellent access to new therapies that, in turn, drive excellent outcomes. As in Germany , the next step will be for the SwissDRG to establish payment for this procedural code based on cost data from major Swiss hospitals. If the new payment is achieved, we expect to accelerate adoption and usage of CytoSorb throughout the country as a life-saving therapy.'“